Search

Your search keyword '"Gondo H"' showing total 328 results
Start Over Author "Gondo H"
328 results on '"Gondo H"'

1. PERBAIKAN FUNGSI TROFOBLAST PADA KADAR β hCG TIKUS BUNTING PREEKLAMPSIA PADA BAHAN BIOLOGIS TERSIMPAN PASCA PERLKUAN DENGAN SPIRULINA

Author

Adhiono , A, Gondo H K, and Noer Kumala I

Subjects
Preeclampsia, Interleukin 6, β hCG, Spirulina, Medicine
Abstract

Abstract: Preeclampsia is multisystem specific disorder in pregnancy. Preeclampsia has signed by increased cytokine Interleukin-6 and β hCG (human Chorionic Gonadotropin). Spirulina is green-blue alga has bioactive compound namely antioxidant, vitamin, mineral. And has benefit namely antinflamation. The aim of this research was to know how spirulina influence to repair trophoblast in Hcg concentration on rat pregnancy (biology material collecting). The type of this research is an experimental laboratoric with post test only control group design. A total of 25 rats with pre-eclampsia models induced by Interleukin 6 are divided into 5 groups: the untreated control group, the positive control group with Interleukin 6 induction for three days, the treatment group with a dose of 10 mg / day, 20 mg / day and 40 mg of spirulina. / day for five day, then the blood serum produced was measured with β hCG levels using ELISA (Enzyme-Linked Immunosorbent Assay). The results of the Spirulina 10 mg / day are higher at 85.11 ± 25.70 mIU / ml from a dose of spirulina 20 mg / day at 79.65 ± 10.65 mIU / ml . In the level of β hCG, the dose group of spirulina 10 mg / day and the group there is no significant difference (0.730> 0.05), the β hCG level group of spirulina 40 mg / day was 93.28 ± 17, 12 mIU / ml from the dose group of spirulina 10 mg / day was 85.11 ± 25.70 mIU / ml. The administration of spirulina for five days was able to reduce β hCG levels at a dose of 10 mg / day, 20 mg / day and 40 mg / day and the dose that was most effective in reducing β hCG levels significantly (P

Published
2018
Full Text
View/download PDF

15. Analysis of 500 bone marrow transplants from unrelated donors (UR-BMT) facilitated by the Japan Marrow Donor Program: confirmation of UR-BMT as a standard therapy for patients with leukemia and aplastic anemia

Author

Kodera, Y, Morishima, Y, Kato, S, Akiyama, Y, Sao, H, Matsuyama, T, Kawa, K, Sakamaki, H, Nakagawa, S, Hirabayashi, N, Dohi, H, Okamoto, S, Hiraoka, A, Gondo, H, Tsuchida, M, O, H, Harada, M, Asano, S, Juji, T, Sasazuki, T, and Takaku, F

Published
1999
Full Text
View/download PDF

32. [Peripheral blood stem cell transplantation for acute leukemia]

Author

Mizuno, S., Toyoshima, M., Niho, Y., Gondo, H., Okamura, T., Otsuka, T., Asano, Y., Makino, S., Taniguchi, S., Akashi, K., Murakawa, M., Takamatsu, Y., Fukuda, T., Ono, H., Iwasaki, H., Kuroiwa, M., Kanechi, Y., Takenaka, K., Tanimoto, K., Shigematsu, H., Yokoyama, T., Osaki, K., Tomofusa Fukuyama, Murakami, T., and Uchida, N.

Subjects
Adult, Male, Leukemia, Myeloid, Acute, Adolescent, Hematopoietic Stem Cell Transplantation, Humans, Antineoplastic Agents, Female, Cell Separation, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Published
1996

33. Role of autotransplantation in the treatment of acute promyelocytic leukemia patients in remission: Fukuoka BMT Group observations and a literature review

Author

Kamimura, T, primary, Miyamoto, T, additional, Nagafuji, K, additional, Numata, A, additional, Henzan, H, additional, Takase, K, additional, Ito, Y, additional, Ohno, Y, additional, Fujisaki, T, additional, Eto, T, additional, Takamatsu, Y, additional, Teshima, T, additional, Gondo, H, additional, Akashi, K, additional, Taniguchi, S, additional, and Harada, M, additional

Published
2010
Full Text
View/download PDF

36. Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation

Author

Mori, T, primary, Mori, S, additional, Kanda, Y, additional, Yakushiji, K, additional, Mineishi, S, additional, Takaue, Y, additional, Gondo, H, additional, Harada, M, additional, Sakamaki, H, additional, Yajima, T, additional, Iwao, Y, additional, Hibi, T, additional, and Okamoto, S, additional

Published
2003
Full Text
View/download PDF

43. Efficient engraftment of primary adult T-cell leukemia cells in newborn NOD/SCID/β2-microglobulinnull mice.

Author

Kawano, N., Ishikawa, F., Shimoda, K., Yasukawa, M., Nagafuji, K., Miyamoto, T., Baba, E., Tanaka, T., Yamasaki, S., Gondo, H., Otsuka, T., Ohshima, K., Shultz, L. D., Akashi, K., and Harada, M.

Subjects
ADULT T-cell leukemia, T cells, GLOBULINS, MICE, PEOPLE with diabetes, LYMPH nodes
Abstract

Adult T-cell leukemia (ATL) develops via multiple oncogenic steps in human T-cell leukemia virus type I (HTLV-I) carriers. To better understand pathogenesis of ATL, we developed a novel xenogeneic engraftment model in which primary ATL cells are intravenously transplanted into neonatal nonobese diabetic (NOD)/severe-combined immunodeficiency (SCID)/β2-microglobulinnull (NOD/SCID/β2mnull) mice. Acute-type ATL cells engrafted in the peripheral blood and in the lymph nodes of recipients at a high efficiency. Engrafted ATL cells were dually positive for human CD4 and CD25, and displayed patterns of HTLV-I integration identical to those of donors by Southern blot analysis. These cells infiltrated into recipients' liver, and formed nodular lesions, recapitulating the clinical feature of each patient. In contrast, in smoldering-type ATL cases, multiple clones of ATL cells engrafted efficiently in NOD/SCID/β2mnull mice. When smoldering-type ATL cells were retransplanted into secondary NOD/SCID/β2mnull recipients, single HTLV-I-infected clones became predominant, suggesting that clones with dominant proliferative activity can be competitively selected in this xenogeneic system. Taken together, the NOD/SCID/β2mnull newborn system is useful to understand kinetics, metastasis, and disease progression of ATL in vivo.Leukemia (2005) 19, 1384–1390. doi:10.1038/sj.leu.2403829; published online 16 June 2005 [ABSTRACT FROM AUTHOR]

Published
2005
Full Text
View/download PDF

44. Donor Leukocyte Infusion for Japanese Patients with Relapsed Leukemia After Allogeneic Bone Marrow Transplantation: Indications and Dose Escalation

Author

Shiobara, S., Nakao, S., Ueda, M., Yamazaki, H., Takahashi, S., Asano, S., Yabe, H., Kato, S., Imoto, S., Maruta, A., Yoshida, T., Gondo, H., Morishima, Y., and Kodera, Y.

Abstract

To clarify the role of dose escalation of donor leukocyte infusion (DLI) in the treatment of relapsed leukemia after allogeneic bone marrow transplant (BMT), data from 100 patients were collected from 46 facilities in Japan and analyzed with respect to indications and infused cell dose. Complete remission (CR) was achieved in 11 of 12 (91%) patients with relapsed chronic myelogenous leukemia (CML) in the chronic phase, 3 of 11 (27%) with CML in the acute phase, 8 of 21 (38%) with acute myelogenous leukemia (AML), 6 of 23 (25%) with acute lymphoblastic leukemia (ALL), and 5 of 11 (45%) with myelodysplastic syndrome (MDS). The probability of remaining in CR at 3 years was 82% in CML patients in the chronic phase, but 0% in those with CML in the acute phase, 7% in those with AML, 0% with ALL, and 33% with MDS. Acute graft-versus-host disease (GVHD) (≥2) developed in 31 of 89 (34%) patients with human leukocyte antigen identical related donors and was fatal for 7 (7%). A leukocyte dose of 1 × 107/kg of recipient body weight with CML in the chronic phase, 3 × 107/kg of recipient body weight with MDS, and 1 × 108/kg of recipient body weight with acute leukemia appeared to be optimal as an initial dose of DLI. However, the minimal dose of leukocyte developing fatal GVHD was 7 × 107/kg of recipient body weight. These suggest that a relatively small dose of DLI ranging from 1 × 107/kg to 5 × 107/kg of recipient body weight should be administered initially then the infused escalating dose 2 or 3 months later in patients with CML in the chronic phase and MDS. However, a large number of leukocytes around 1 × 108/kg are needed to induce graft versus leukemia effects in patients with acute leukemia despite a 7% fatality in GVHD.

Published
2001
Full Text
View/download PDF

46. Oral involvement in chronic graft-versus-host disease after allogeneic bone marrow transplantation

Author

Nakamura, S., Hiroki, A., Shinohara, M., Gondo, H., Ohyama, Y., Mouri, T., Sasaki, M., Shirasuna, K., Harada, M., and Niho, Y.

Abstract

We examined 37 patients who had undergone an allogeneic bone marrow transplantation and compared their oral findings to their systemic involvement with chronic graft-versus-host disease. Among the clinical signs and symptoms in their oral region, only the presence of oral lichenoid lesions had a statistically significant relationship to the diagnosis of chronic graft-versus-host disease. The histologic findings in the labial salivary glands and buccal mucosa closely reflected the status of chronic graft-versus-host disease. Statistically, the presence of diffuse and periductal lymphocytic infiltration in labial salivary glands, subepithelial lymphocytic infiltration and epithelial changes in buccal mucosa also showed a significant relationship to the diagnosis of chronic graft-versus-host disease. The present study suggests that a systematic oral examination, especially pathologic examination of the labial salivary glands and buccal mucosa, is useful in evaluating the status of chronic graft-versus-host disease.

Published
1996
Full Text
View/download PDF

47. A comparison of glandular involvement between chronic graft-versus-host disease and Sjogren's syndrome

Author

Hiroki, A., Nakamura, S., Shinohara, M., Gondo, H., Ohyama, Y., Hayashi, S., Harada, M., Niho, Y., and Oka, M.

Abstract

Patients with chronic graft-versus-host disease (cGVHD) occasionally suffer from symptoms of xerostomia and xerophthalmia, which are also features of Sjogren's syndrome (SS). To identify differences in the glandular involvement between cGVHD and SS, we measured the proportions of infiltrating lymphocyte subsets and the expression of HLA-DR antigen and cell adhesion molecules in labial salivary glands (LSG). In cGVHD, more than 90% of the infiltrating lymphocytes were T cells with a slight predominance of CD8^+ over CD4^+ cells. In SS, CD4^+ cells were predominant, and B cells accounted for 10-30% of the infiltrating lymphocytes. Ductal epithelial cells associated with lymphocytic infiltration expressed HLA-DR antigen in both cGVHD and SS. In SS alone, HLA-DR antigen expression also occurred without associated lymphocytic infiltration. The expression of adhesion molecules on ductal epithelial cells, especially vascular cell adhesion molecule-1, was more intense in SS than in cGVHD, while that on endothelial cells was similar in cGVHD and SS. These data suggest that the pathogenesis of glandular involvement of cGVHD is different from that of SS.

Published
1996
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results